Avalon GloboCare (NASDAQ:CHGA) versus MongoDB (NASDAQ:MDB) Critical Review

MongoDB (NASDAQ:MDB) and Avalon GloboCare (NASDAQ:CHGA) are both technology companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Profitability

This table compares MongoDB and Avalon GloboCare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MongoDB	2.12%	1.06%	0.84%
Avalon GloboCare	N/A	N/A	-53.69%

Risk & Volatility

MongoDB has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500. Comparatively, Avalon GloboCare has a beta of -0.05, suggesting that its share price is 105% less volatile than the S&P 500.

Institutional and Insider Ownership

89.3% of MongoDB shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 2.6% of MongoDB shares are held by insiders. Comparatively, 24.2% of Avalon GloboCare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for MongoDB and Avalon GloboCare, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MongoDB	0	6	28	2	2.89
Avalon GloboCare	1	0	0	0	1.00

MongoDB presently has a consensus target price of $471.81, suggesting a potential upside of 39.92%. Given MongoDB’s stronger consensus rating and higher probable upside, equities analysts plainly believe MongoDB is more favorable than Avalon GloboCare.

Valuation and Earnings

This table compares MongoDB and Avalon GloboCare”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MongoDB	$2.46 billion	11.03	-$71.15 million	$0.71	474.92
Avalon GloboCare	$1.26 million	1.74	-$18.26 million	($13.80)	-0.14

Avalon GloboCare has lower revenue, but higher earnings than MongoDB. Avalon GloboCare is trading at a lower price-to-earnings ratio than MongoDB, indicating that it is currently the more affordable of the two stocks.

Summary

MongoDB beats Avalon GloboCare on 13 of the 15 factors compared between the two stocks.

About MongoDB

MongoDB, Inc., together with its subsidiaries, provides general purpose database platform worldwide. The company provides MongoDB Atlas, a hosted multi-cloud database-as-a-service solution; MongoDB Enterprise Advanced, a commercial database server for enterprise customers to run in the cloud, on-premises, or in a hybrid environment; and Community Server, a free-to-download version of its database, which includes the functionality that developers need to get started with MongoDB. It offers professional services comprising consulting and training. The company was formerly known as 10gen, Inc. and changed its name to MongoDB, Inc. in August 2013. MongoDB, Inc. was incorporated in 2007 and is headquartered in New York, New York.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.